Analysts coverage and consensus
Analyst coverage
Below are listed the sell-side analysts that cover Givaudan on a regular basis.
| Institution | Name | Recommendation |
| Baader Helvea | Konstantin Wiechert | reduce |
| Bank of America | Matthew Yates | neutral |
| Barclays | Alex Sloane | equal weight |
| Berenberg Bank | Samantha Darbyshire | hold |
| BNP Paribas Exane | Nicola Tang | neutral |
| Bryan Garnier | Philippine Adam | buy |
| CIC | Virginie Royere Roumage | neutral |
| Citi Investment Research | Ranulf Orr | buy |
| Davy Research | Cathal Kenny | neutral |
| Deutsche Bank | Virginie Boucher-Ferté | hold |
| DZ Bank AG | Thomas Maul | hold |
| Goldman Sachs International | Georgina Fraser | buy |
| Jefferies | Charles Bentley | underperform |
| JP Morgan | Celine Pannuti | neutral |
| Kepler Cheuvreux | Patrick Roquas | buy |
| Mirabaud | Anja Pomrehn | hold |
| Morgan Stanley | Lisa De Neve | underweight |
| Morningstar | Diana Radu | underperform |
| Redburn Atlantic | Artem Chubarov | neutral |
| Research Partners | Eugen Perger | hold |
| Stifel Europe Bank AG | Isha Sharma | hold |
| UBS | Charles Eden | neutral |
| Van Lanschot Kempen | Eric Wilmer | neutral |
| Vontobel | Arben Hasanaj | buy |
| Zürcher Kantonalbank | Daniel Buerki | outperform |
Consensus
The consensus forecasts, compiled by Givaudan, are based on emails and reports received between 18 June and 1 July 2024.
Disclaimer:
The consensus forecast set out below results from regular research reports made by analysts currently covering Givaudan, as detailed in the list below. This list has been drawn up to the best of Givaudan’s knowledge but does not purport to be comprehensive of all institutions publishing financial research on Givaudan.
Any opinions, forecasts, estimates, projections or predictions regarding Givaudan’s performance made by the analysts are exclusively theirs and do not represent the opinions, forecasts, estimates, projections or predictions of Givaudan or its management. The publication of this information on this website does not imply that Givaudan endorses, or concurs with, the reports, conclusions or recommendations of the cited analysts. Givaudan disclaims any liability for the accuracy or completeness of such information and does not assume any obligation to update it even if it becomes aware of any changes.
This information is provided for ease of reference only and does not constitute an offer or solicitation to buy, hold or sell Givaudan securities.
| in millions of Swiss francs | FY 2023 A | FY 2024 E | FY 2025 E | HY 2023 A | HY 2024 | Q2 2024 | |
| Group sales | 6,915 | 3,535 | |||||
| High | 7,611 | 8,089 | 3,844 | 2,022 | |||
| Average | 7,302 | 7,656 | 3,701 | 1,885 | |||
| Low | 7,071 | 7,377 | 3,535 | 1,733 | |||
| LFL Group sales growth (%) | 4.1% | 2.4% | |||||
| High | 12.4% | 5.5% | 14.3% | 15.9% | |||
| Average | 9.3% | 4.6% | 12.4% | 12.1% | |||
| Low | 4.9% | 3.2% | 10.0% | 7.1% | |||
| Fragrance & Beauty ( F&B) sales | 3,312 | 1,672 | |||||
| High | 3,713 | 3,957 | 1,864 | 964 | |||
| Average | 3,555 | 3,727 | 1,809 | 911 | |||
| Low | 3,425 | 3,572 | 1,717 | 817 | |||
| LFL F&B sales growth (%) | 7.6% | 6.4% | |||||
| High | 14.4% | 6.3% | 17.6% | 17.0% | |||
| Average | 10.6% | 4.6% | 15.2% | 13.8% | |||
| Low | 5.0% | 2.2% | 11.2% | 5.7% | |||
| Taste & Wellbeing (T&W) sales | 3,603 | 1,863 | |||||
| High | 3,898 | 4,132 | 1,980 | 1,058 | |||
| Average | 3,753 | 3,932 | 1,900 | 979 | |||
| Low | 3,634 | 3,805 | 1,838 | 916 | |||
| LFL T&W sales growth (%) | 1.1% | -0.9% | |||||
| High | 10.9% | 5.1% | 12.1% | 15.0% | |||
| Average | 8.5% | 4.5% | 10.1% | 10.8% | |||
| Low | 4.6% | 3.9% | 7.9% | 6.5% | |||
| Comparable EBITDA Group | 1,547 | 803 | |||||
| High | 1,863 | 1,942 | 974 | ||||
| Average | 1,729 | 1,824 | 901 | ||||
| Low | 1,616 | 1,734 | 831 | ||||
| Comparable EBITDA margin (%) | 22.4% | 22.7% | |||||
| High | 24.5% | 24.4% | 25.5% | ||||
| Average | 23.7% | 23.8% | 24.4% | ||||
| Low | 22.8% | 22.8% | 23.2% | ||||
| Fragrance & Beauty (F&B) sales | 817 | 406 | |||||
| High | 999 | 1,010 | 522 | ||||
| Average | 904 | 939 | 467 | ||||
| Low | 841 | 881 | 422 | ||||
| F&B EBITDA margin (%) | 24.7% | 24.3% | |||||
| High | 26.9% | 25.9% | 28.0% | ||||
| Average | 25.4% | 25.1% | 25.8% | ||||
| Low | 24.5% | 23.8% | 24.5% | ||||
| Taste & Wellbeing (T&W) sales | 730 | 397 | |||||
| High | 870 | 931 | 462 | ||||
| Average | 817 | 879 | 430 | ||||
| Low | 773 | 821 | 389 | ||||
| T&W EBITDA margin (%) | 20.3% | 21.3% | |||||
| High | 23.0% | 23.4% | 24.3% | ||||
| Average | 21.8% | 22.4% | 22.6% | ||||
| Low | 20.4% | 21.2% | 21.0% | ||||
| Reported EBITDA | 1,473 | 763 | |||||
| High | 1,813 | 1,902 | 949 | ||||
| Average | 1,684 | 1,799 | 875 | ||||
| Low | 1,570 | 1,685 | 806 | ||||
| Reported EBITDA margin (%) | 21.3% | 21.6% | |||||
| High | 23.8% | 24.2% | 24.8% | ||||
| Average | 23.0% | 23.5% | 23.7% | ||||
| Low | 22.2% | 22.2% | 22.7% | ||||
| Net income reported | 893 | 449 | |||||
| High | 1,122 | 1,171 | 597 | ||||
| Average | 1,016 | 1,116 | 533 | ||||
| Low | 908 | 1,028 | 473 | ||||
| Free cash flow reported | 920 | 104 | |||||
| High | 1,154 | 1,170 | 415 | ||||
| Average | 1,003 | 1,073 | 267 | ||||
| Low | 817 | 886 | 129 | ||||
| Free cash flow as a % of sales | 13.3% | 2.9% | |||||
| High | 16.0% | 15.5% | 11.3% | ||||
| Average | 13.7% | 14.0% | 7.2% | ||||
| Low | 11.2% | 11.7% | 3.4% | ||||
| Price target | |||||||
| High | 4,800 | ||||||
| Average | 4,066 | ||||||
| Low | 3,000 | ||||||
| Recommendation | |||||||
| Buy | 5 | ||||||
| Hold | 11 | ||||||
| Sell | 3 | ||||||
| Number of estimates | 19 | ||||||
| Latest update | 03-07-2024 | ||||||
Note: numbers might not sum-up because of rounding.
